Prasanna Jagannathan
Overview
Explore the profile of Prasanna Jagannathan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
140
Citations
3348
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Benjamin-Chung J, Tong Y, Roh M, Jagannathan P
EBioMedicine
. 2025 Jan;
112:105546.
PMID: 39778289
No abstract available.
2.
Roh M, Gutman J, Murphy M, Hill J, Madanitsa M, Kakuru A, et al.
medRxiv
. 2024 Dec;
PMID: 39649586
Background: High-grade resistance to sulfadoxine-pyrimethamine in East and Southern Africa has prompted numerous trials evaluating intermittent preventive treatment in pregnancy (IPTp) with dihydroartemisinin-piperaquine as an alternative to sulfadoxine-pyrimethamine. Methods: We...
3.
Lindsell C, Shotwell M, Anstrom K, Berry S, Brittain E, Harrell F, et al.
J Clin Transl Sci
. 2024 Dec;
8(1):e177.
PMID: 39619071
[This corrects the article DOI: 10.1017/cts.2024.514.].
4.
Keshtkar-Jahromi M, Adam S, Brar I, Chung L, Currier J, Daar E, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e152.
PMID: 39540114
The United States Government (USG) public-private partnership "Accelerating COVID-19 Treatment Interventions and Vaccines" (ACTIV) was launched to identify safe, effective therapeutics to treat patients with Coronavirus Disease 2019 (COVID-19) and...
5.
Lindsell C, Shotwell M, Anstrom K, Berry S, Brittain E, Harrell F, et al.
J Clin Transl Sci
. 2024 Nov;
8(1):e155.
PMID: 39540110
The Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) Cross-Trial Statistics Group gathered lessons learned from statisticians responsible for the design and analysis of the 11 ACTIV therapeutic master protocols to...
6.
Sex differences and immune correlates of Long Covid development, symptom persistence, and resolution
Hamlin R, Pienkos S, Chan L, Stabile M, Pinedo K, Rao M, et al.
Sci Transl Med
. 2024 Nov;
16(773):eadr1032.
PMID: 39536117
Sex differences have been observed in acute coronavirus disease 2019 (COVID-19) and Long Covid (LC) outcomes, with greater disease severity and mortality during acute infection in males and greater proportions...
7.
Tukwasibwe S, Lewis S, Taremwa Y, van der Ploeg K, Press K, Ty M, et al.
Clin Transl Immunology
. 2024 Nov;
13(11):e70005.
PMID: 39493859
Objectives: Natural killer (NK) cells make important contributions to anti-malarial immunity through antibody-dependent cellular cytotoxicity (ADCC), but the role of different components of this pathway in promoting NK cell activation...
8.
Keshtkar-Jahromi M, Anstrom K, Barkauskas C, Brown S, Daar E, Fischer W, et al.
J Clin Transl Sci
. 2024 Oct;
8(1):e151.
PMID: 39478775
Accelerating COVID-19 Treatment Interventions and Vaccines (ACTIV) was initiated by the US government to rapidly develop and test vaccines and therapeutics against COVID-19 in 2020. The ACTIV Therapeutics-Clinical Working Group...
9.
Reyes R, Turner L, Ssewanyana I, Jagannathan P, Feeney M, Lavstsen T, et al.
PLoS Pathog
. 2024 Oct;
20(10):e1012661.
PMID: 39466842
Plasmodium falciparum infections elicit strong humoral immune responses to two main groups of antigens expressed by blood-stage parasites: merozoite antigens that are involved in the erythrocyte invasion process and variant...
10.
Rothman R, Stewart T, Mourad A, Boulware D, McCarthy M, Thicklin F, et al.
JAMA Netw Open
. 2024 Oct;
7(10):e2439332.
PMID: 39422912
Importance: The effect of montelukast in reducing symptom duration among outpatients with mild to moderate COVID-19 is uncertain. Objective: To assess the effectiveness of montelukast compared with placebo in treating...